Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million series B financing round. The round was led by Veradigm, with participation from current investors including Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health, as well as other previous investors.
This topic aims at supporting activities that are enabling or contributing to one or several impacts of destination 1 "Staying healthy in a rapidly changing society". To that end, proposals under this topic should aim for delivering results that are directed at, tailored towards and contributing to all of the following expected outcomes:
To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI.
Together with Member States, the Commission is co-funding the TEFs to support AI developers to bring trustworthy AI to the market more efficiently, and facilitate its uptake in Europe.
Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run cutting-edge machine learning models and computationally-intensive workloads, to help accelerate and scale Bayer's quantum chemistry calculations.
The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the SpinLab team works to ensure that promising startups receive all the necessary resources as well as sufficient professional support for long-term success in the market.
Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand during 2022, and Allscripts will now formally be known as Veradigm.
Current DNA mutation software detectors, while scanning the 3 billion bases of the human genome, are not well suited to discern mosaic mutations hiding among normal DNA sequences.